New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
EBV-Positive Nodular Lymphocyte Predominant Hodgkin Lymphoma: A Single Institution Experience.
ÌÇÐÄ´«Ã½
EBV-Positive Nodular Lymphocyte Predominant Hodgkin Lymphoma: A Single Institution Experience. Human pathology Fei, F., Kiruthiga, K. G., Younes, S., Natkunam, Y. 2022Abstract
OBJECTIVE: To characterize the clinicopathologic features of EBV-positive nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) at a single institution.METHODS: A retrospective review of cases diagnosed with EBV-positive NLPHL was performed and the patients' demographic and pathologic features were collected by chart review.RESULTS: We identified 17 EBV-positive NLPHL patients whose clinicopathologic features are characterized. EBV was positive in lymphocyte predominant (LP) cells in 6 of 17 cases while the remaining cases showed EBV positivity in background small cells. Immunohistochemical analysis showed that LP cells were positive for CD20 (94.1%) in the majority of cases and positive for OCT2 (100%) in all cases with one case showing weak OCT2 expression, while PAX5 and CD79a were weak and/or variable in 9 of 12 and 3 of 7 cases, respectively. CD30 was positive in 7 of 17 cases with 5 cases showing only scattered positive cells. In addition, we report a patient who had a history of EBV-negative NLPHL and showed EBV-positive NLPHL at the time of recurrence. Molecular studies performed on the two biopsies in the patient indicated EBV infection involving the NF-kB pathway.CONCLUSIONS: Our study shows that EBV-positive NLPHL is rare and may be diagnostically challenging due to atypical immunophenotypic features, such as partial expression of CD30, and weak/variable PAX5 and/or CD79a expression. The overall retention of the B-cell phenotype with strong and diffuse expression of CD20 and OCT2 in LP cells, supports the diagnosis of EBV-positive NLPHL.
View details for
View details for